These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 20478328)
41. Chronic intracerebroventricular infusion of nociceptin/orphanin FQ produces body weight gain by affecting both feeding and energy metabolism in mice. Matsushita H; Ishihara A; Mashiko S; Tanaka T; Kanno T; Iwaasa H; Ohta H; Kanatani A Endocrinology; 2009 Jun; 150(6):2668-73. PubMed ID: 19196798 [TBL] [Abstract][Full Text] [Related]
42. Association of olanzapine-induced weight gain with an increase in body fat. Eder U; Mangweth B; Ebenbichler C; Weiss E; Hofer A; Hummer M; Kemmler G; Lechleitner M; Fleischhacker WW Am J Psychiatry; 2001 Oct; 158(10):1719-22. PubMed ID: 11579009 [TBL] [Abstract][Full Text] [Related]
43. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368 [TBL] [Abstract][Full Text] [Related]
44. Adiposity and eating behaviors in patients under second generation antipsychotics. Blouin M; Tremblay A; Jalbert ME; Venables H; Bouchard RH; Roy MA; Alméras N Obesity (Silver Spring); 2008 Aug; 16(8):1780-7. PubMed ID: 18535555 [TBL] [Abstract][Full Text] [Related]
45. The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats. Ortmann S; Kampe J; Gossel M; Bickel M; Geisen K; Jähne G; Lang HJ; Klaus S Obes Res; 2004 Aug; 12(8):1290-7. PubMed ID: 15340112 [TBL] [Abstract][Full Text] [Related]
46. Induction of subcutaneous adipose proliferation by olanzapine in rodents. Tan W; Fan H; Yu PH Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1098-103. PubMed ID: 20541579 [TBL] [Abstract][Full Text] [Related]
47. High-fat diet meal patterns during and after continuous nicotine treatment in male rats. Mendez IA; Carcoba L; Wellman PJ; Cepeda-Benito A Exp Clin Psychopharmacol; 2016 Dec; 24(6):477-484. PubMed ID: 27643914 [TBL] [Abstract][Full Text] [Related]
48. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Minet-Ringuet J; Even PC; Valet P; Carpéné C; Visentin V; Prévot D; Daviaud D; Quignard-Boulange A; Tomé D; de Beaurepaire R Mol Psychiatry; 2007 Jun; 12(6):562-71. PubMed ID: 17211438 [TBL] [Abstract][Full Text] [Related]
49. Spontaneous meal patterns in female rats with and without access to running wheels. Eckel LA; Houpt TA; Geary N Physiol Behav; 2000; 70(3-4):397-405. PubMed ID: 11006440 [TBL] [Abstract][Full Text] [Related]
50. Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Kirk SL; Neill JC; Jones DN; Reynolds GP Eur J Pharmacol; 2004 Nov; 505(1-3):253-4. PubMed ID: 15556160 [TBL] [Abstract][Full Text] [Related]
51. Influence of high-fat feeding, diet-induced obesity, and hyperamylinemia on the sensitivity to acute amylin. Boyle CN; Rossier MM; Lutz TA Physiol Behav; 2011 Jul; 104(1):20-8. PubMed ID: 21550355 [TBL] [Abstract][Full Text] [Related]
52. An animal model of antipsychotic-induced weight gain. Arjona AA; Zhang SX; Adamson B; Wurtman RJ Behav Brain Res; 2004 Jun; 152(1):121-7. PubMed ID: 15135975 [TBL] [Abstract][Full Text] [Related]
53. Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagia, and metabolic dysregulation in mice. Coccurello R; Caprioli A; Conti R; Ghirardi O; Borsini F; Carminati P; Moles A J Pharmacol Exp Ther; 2008 Sep; 326(3):905-11. PubMed ID: 18567835 [TBL] [Abstract][Full Text] [Related]
57. Obestatin reduces food intake and suppresses body weight gain in rodents. Lagaud GJ; Young A; Acena A; Morton MF; Barrett TD; Shankley NP Biochem Biophys Res Commun; 2007 May; 357(1):264-9. PubMed ID: 17418097 [TBL] [Abstract][Full Text] [Related]
58. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Beebe KL; Block T; Debattista C; Blasey C; Belanoff JK Behav Brain Res; 2006 Aug; 171(2):225-9. PubMed ID: 16782211 [TBL] [Abstract][Full Text] [Related]
59. Individual differences in the feeding and locomotor stimulatory effects of acute and repeated morphine treatments. Sills TL; Vaccarino FJ Pharmacol Biochem Behav; 1998 May; 60(1):293-303. PubMed ID: 9610955 [TBL] [Abstract][Full Text] [Related]
60. Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. Remington G; Mann S; McCormick P; Nobrega JN; Hahn M; Natesan S Pharmacol Biochem Behav; 2011 Nov; 100(1):86-9. PubMed ID: 21839766 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]